Seedlabs

Thrombolysis Contraindication Re-Screener and Missed-Patient Audit

A tool that checks if stroke patients were wrongly denied clot-busting drugs based on old medical rules.

A bedside EHR tool that checks stroke patients against the 2026 guideline's revised approach to clot-buster contraindications, plus a retrospective audit that finds patients who were denied treatment under outdated 2018-era exclusion rules.

MedicineAcute Ischemic Stroke Management
Attention Deficit Hyperactivity DisorderEmergency medicine acute stroke clinical decision support

Concept

Every ED's stroke workflow embeds a contraindication checklist that decides who receives IV thrombolysis. The 2026 guideline explicitly modifies the approach to thrombolysis contraindications and updates thrombolytic choice and eligibility — so checklists built on 2018-era exclusion lists will wrongly deny some eligible patients and misapply the new thrombolytic selection logic. The product has two parts. First, a bedside re-screener inside the ED stroke workflow: it pulls the patient's history, medications, and labs, and outputs which 2026 contraindications apply, which legacy exclusions no longer do, and a chart-ready rationale. Second, a retrospective audit mode: it runs the 2026 logic over the past year of AIS encounters and quantifies patients who were excluded under old rules but would have been candidates — giving stroke programs a numbers-backed case for retraining and order-set revision. The wedge is patient-level eligibility safety at the moment of decision, not content management.

Why now

The abstract lists modification of the thrombolysis-contraindication approach and new evidence on thrombolytic choice and eligibility among the headline changes of the first comprehensive revision since 2018 — meaning every embedded exclusion checklist predates the current standard. Mining EHR data to surface patients missed by outdated criteria is an established technique (NLP and coded-data screening identified under-recognized AL amyloidosis in records [3]), so the retrospective audit mode is credible with data hospitals already hold.

Written by GLM · 8 Oct 2026

AI assessment

Backed by 2 papers83

A high-utility clinical decision support tool that leverages a major guideline shift to drive immediate adoption through a 'missed-patient' audit.

Evidence strength
5/5
The idea is directly grounded in the 2026 AHA/ASA guideline update, and the retrospective audit mechanism is supported by the provided research on EHR mining for rare/under-diagnosed conditions.
Market pull
4/5
Hospital stroke programs have high urgency to adhere to new guidelines to avoid liability and improve outcomes, making them strong buyers.
Novelty & moat
3/5
While similar to 'Stroke Pathway Resync', this shifts from a consulting/mapping service to a functional software tool with a retrospective audit 'hook'.
Feasibility
4/5
Building a logic-based screener and a retrospective query tool is technically straightforward provided there is EHR integration.
Wedge clarity
5/5
The retrospective audit is a brilliant wedge; it proves the value of the tool by quantifying exactly how many patients were wrongly denied treatment under old rules.
Simplicity / focus
4/5
The product is focused on a single clinical decision point (thrombolysis eligibility) and a single validation method (audit).

Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Epic Systemscompany

    Health systems build thrombolysis workflows in Epic; a maintained 2026 contraindication module lets its customers update eligibility logic without local custom builds.

  • Mass General Brighamorganization

    High-volume stroke centers and telestroke networks can run the retrospective audit across member EDs to quantify wrongly excluded patients and drive protocol updates network-wide.

  • Viz.aicompany

    Its stroke coordination platform already sits in the acute workflow; adding a current contraindication re-screener closes the gap between AI triage and guideline-current treatment eligibility.

  • Genentechcompany

    Manufacturer of alteplase and tenecteplase; a tool that safely applies the revised contraindication approach and quantifies eligible-but-missed patients supports appropriate utilization of its thrombolytics.

  • American College of Emergency Physiciansorganization

    Emergency physicians carry liability when embedded checklists lag guideline changes; an always-current re-screener reduces that exposure for their members.

Research it builds on

  1. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association
    Shyam Prabhakaran, Nestor R. Gonzalez, Kori Sauser Zachrison et al. · 2026 · 263 citations
    All ideas from this paper →
  2. Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data
    Eli Silvert, Laura Hester, Eshwan Ramudu et al. · 2023 · 5 citations
    All ideas from this paper →
Leave feedback
feasibility